Safety and efficacy results of Diversion-p64 in comparison with similar prospective non-randomized studies involving other flow diverters
| Study | p64 (Diversion-p64) | PED (PREMIER) | FRED (SAFE) | Surpass | Derivo |
| Time point of last follow-up | 12 months | 12 months | 12 months | 6 months | 18 months |
| Number of aneurysms | 420 | 141 | 103 | 186 | 96 |
| Anterior circulation | 100% | 95% | 100% | 85.5% | 88% |
| Average aneurysm size (mm) | 6.99±5.28 | 5.0±1.92 | Not Reported | 10.4±0.7 | 14.2±16.9 |
| Percentage of adjunctive coiling | 14% | 3.5% | 22.4% | 19.3% | 49% |
| Patients with safety follow-up at 12 months | 88.6% | 99.2% | 95.1% | 93.2% | 93.8% |
| Morbidity | 1.6% | 1.4% | 2.9% | 6.0%* | 3.1% |
| Mortality | 1.1% | 0.7% | 1.9% | 2.7%† | 0.0% |
| Complete occlusion | 83.7% | 81.9% | 73.3% | 75% | 82% |
*4% permanent morbidity for treated anterior circulation aneurysms.
†1.7% mortality for treated anterior circulation aneurysms.
FRED, flow redirection endoluminal device ; PED, Pipeline embolization device.